<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754842</url>
  </required_header>
  <id_info>
    <org_study_id>AU2018-11-19</org_study_id>
    <nct_id>NCT03754842</nct_id>
  </id_info>
  <brief_title>Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans</brief_title>
  <official_title>Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans - A Randomized, Placebo-controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Successful skeletal muscle regeneration depends on a functional pool of muscle stem cells,
      termed satellite cells (SC). SC are in a quiescent state throughout adulthood, but undergo
      multiple cycles of proliferation and self-renewal in response to muscle damage. During aging,
      there is a loss of SC quiescence, and SC more readily enter an ageing-state impairing their
      function.

      Animal studies have revealed a common denominator for increasing SC function and activity,
      namely Sirtuin activation. Natural stimulators of Sirtuins includes Nicotinamide Riboside
      (NR) (a Nicotinamide adenine dinucleotide (NAD+) precursor) and the polyphenol Pterostilbene
      (PT). In this study, we aim to investigate if NR+PT supplementation will promote skeletal
      muscle regeneration after muscle damage in elderly humans by enhanced recruitment of SC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      14 days after start of placebo or NR/PT (500/100 mg twice daily) supplementation a muscle
      damage will induced in the m. vastus lat. by electric stimulation combined with eccentric
      work in a dynamometer. Muscle biopsies will be collected at 2 hours, 2, 8 and 30 days post
      damage and placebo or NR/PT supplementation will continue for the whole study period (45
      days).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Satellite Cells</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>quantified by immunohistochemistry in muscle biopsies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of Satellite cells</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined by immunohistochemistry and FACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of macrophages</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined by immunohistochemistry and FACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Fibro/Adipogenic Progenitors</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>quantified by FACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of damaged muscle fibers</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of muscle regenerative fibers</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of autophagy in relation to muscle damage</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined by Western blot and PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid accumulation in skeletal muscle tissue and liver</measure>
    <time_frame>Change from baseline to 8 days</time_frame>
    <description>determined by magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose response in relation to muscle damage</measure>
    <time_frame>Change from baseline to 8 days</time_frame>
    <description>determined by Continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition (lean body mass and fat body mass)</measure>
    <time_frame>Change from baseline to 45 days</time_frame>
    <description>measured by Dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Change from baseline up to 45 days</time_frame>
    <description>determined from maximal voluntary contraction of the m. quadriceps femoris</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Muscle Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside + Pterostilbene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (twice daily)</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)</intervention_name>
    <description>Elysium Basis TM, Elysium Health, Inc., NY, USA</description>
    <arm_group_label>Nicotinamide Riboside + Pterostilbene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written signed consent

          -  Age: 55-80

          -  BMI: 20-28 (kg/(m2))

          -  Non-smoker

        Exclusion Criteria:

          -  Endocrine disease, neurological or muscle disease

          -  Other severe disease

          -  High daily activity level (&gt;30 min / day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonas B. Jensen</last_name>
    <phone>0045 40952577</phone>
    <email>jonj@biomed.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Jessen</last_name>
    <phone>0045 28596352</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Jensen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

